• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Public Workshop: Risks and Benefits of Hydroxyethyl Starch Solutions

September 6, 2012
8:00 a.m. - 5:30 p.m.

September 7, 2012
8:30 a.m. - 1:00 p.m

Workshop Goals and Objectives

The Food and Drug Administration (FDA) is announcing a public workshop entitled: “Risks and Benefits of Hydroxyethyl Starch Solutions.&rdquo The purpose of this public workshop is to discuss new information on the risks and benefits of FDA-approved hydroxyethyl starch (HES) solutions.

The public workshop has been planned in partnership with the Department of Defense and the National Heart, Lung and Blood Institute, National Institutes of Health and HHS Office of the Assistant Secretary for Health and will include presentations and panel discussions with experts from academia, regulated industry, government, and other stakeholders.

HES solutions are synthetic colloids administered intravenously to patients to maintain or expand plasma volume when clinically indicated. Currently, three such products are approved by FDA. HES solutions are indicated for the treatment of hypovolemia (low blood volume) that may result from trauma, sepsis, burns, or anaphylaxis. These products are used in the prehospital and hospital environment in both military and civilian settings. This public workshop will serve as a forum for discussing new information on the potential effects of HES solutions on hemostasis and on the renal system.

The first day of the public workshop will include presentations and panel discussions on the following topics: (1) The risks and benefits associated with HES solutions in different clinical settings and (2) the findings of two recent major clinical studies conducted on HES solutions.

The second day of the public workshop will include a summary discussion and presentations concerning the overall safety profile of HES solutions and a discussion of future clinical research for the evaluation of HES solutions.

Location

Masur Auditorium
Clinical Center Building 10
National Institutes of Health
9000 Rockville Pike
Bethesda, MD 20892

Please visit http://www.nih.gov/about/visitor/index.htm for NIH campus maps and NIH visitor information on security requirements, visitor parking and public transportation. Please allow sufficient time to clear security screening at the NIH Gateway Center upon your arrival at the NIH campus.

Registration

Mail, fax, or email your registration information (including name, title, firm or organization name, address, telephone and fax numbers, and email address) to Jennifer Scharpf (see Contact Person) by August 15, 2012. There is no registration fee for the public workshop. Early registration is recommended because seating is limited. Registration on the day of the public workshop will be provided on a space available basis beginning at 7:00 a.m. If you need special accommodations due to a disability, please contact Jennifer Scharpf (see Contact Person) at least 7 days in advance.

Contact Person

Jennifer Scharpf, MPH
Food and Drug Administration
Office of Blood Research & Review
Center for Biologics Evaluation and Research
1401 Rockville Pike, HFM-300
Rockville, MD 20852
Phone: 301-827-6128
Fax: 301-827-2843
e-mail: CBEROBRRWorkshops@fda.hhs.gov